BioArctic AB (publ) (STO: BIOA.B)
Sweden
· Delayed Price · Currency is SEK 199.50
-4.10 (-2.01%)
Dec 30, 2024, 5:29 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 76.63M SEK in the quarter ending September 30, 2024, a decrease of -63.31%. This brings the company's revenue in the last twelve months to 167.14M, down -72.46% year-over-year. In the year 2023, BioArctic AB had annual revenue of 616.00M with 168.49% growth.
Revenue (ttm)
167.14M
Revenue Growth
-72.46%
P/S Ratio
110.84
Revenue / Employee
1.61M
Employees
88
Market Cap
18.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
| Dec 31, 2019 | 282.94M | -439.28M | -60.82% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 1, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 25.44B |
| Sectra AB | 3.14B |
| Getinge AB | 33.59B |
| Camurus AB | 1.69B |
| Vitrolife AB | 3.56B |
| Bonesupport Holding AB | 814.46M |
| Elekta AB | 17.72B |
| Vimian Group AB | 3.99B |
BioArctic AB News
- 4 weeks ago - Leqembi® approved in Mexico - PRNewsWire
- 5 weeks ago - Leqembi® launched in South Korea - PRNewsWire
- 7 weeks ago - CHMP issues positive recommendation for approval of lecanemab in the EU - PRNewsWire
- 7 weeks ago - Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion - PRNewsWire
- 2 months ago - Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET - PRNewsWire
- 2 months ago - Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile - PRNewsWire
- 2 months ago - Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 - Benzinga
- 2 months ago - Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease - PRNewsWire